... settled all matters with GlaxoSmithKline (NYSE:GSK) (GSK) related to its Sumatriptan Succinate tablets, the generic version of GSK's Imitrex tablets. ...
L: Quote, Profile, Research) on a possible patent litigation for a generic version of the firm's Imitrex tablets, propping its share up in a falling market. ...
all 19 news articles
Ranbaxy has announced a patent settlement relating to Imitrex with GSK Pharmacueticals. Ranbaxy will launch a generic version of Imitrex and Sumatriptan in ...
Annual sales for Imitrex are $985 million, according to statistics cited by Ranbaxy. Imitrex is also sold as a nasal spray and an injection.
According to IMS figures, Imitrex had annual sales of $985 million in 2007, a Ranbaxy Laboratories release said. Other details of the settlement were not ...
L), all matters relating to a possible patent litigation for a generic version of the firm's Imitrex tablets. Terms of the deal were not disclosed. ...
Sumatriptan Succinate tablets are the generic version of GlaxoSmithKline's Imitrex Tablets. The terms of the settlement provide that Ranbaxy may distribute ...
The annual market sales for Sumatriptan Succinate (Imitrex(R)) were USD 985 million (IMS-MAT: Sept 2007). Ranbaxy Laboratories Limited, India's largest ...
... said it has settled all matters with GlaxoSmithKline (GSK) related to its Sumatriptan Succinate tablets, the generic version of GSK's Imitrex tablets. ...